Achalasia is rare disease which upsets the esophagus making the passage of the food difficult. It is a disease with unidentified cause but few genetic factors as well as neuro-muscular disorders are connected to the disease. Achalasia lowers the food passing capacity by narrowing the muscles around the esophagus in turn reducing the cavity through which food passes and affects the lower part of the esophagus. In the united states the prevalence of the achalasia is about 10 in every 100,000 of general population. The onset of the achalasia does not depend on age but it mostly affects elderly population.. Global Achalasia Treatment market was valued, in 2019 USD XX million and in 2024 is expected to reach at USD XX million with growing CAGR of XX%.
The global achalasia treatment market is increasing due to growth in research grants and R&D expenditure form governments. Also growing government support is encouraging the enlargement of treatment options for achalasia and is predictable to change the landscape of achalasia treatment over the forecast period.
Moreover the existence of a small number of affected people is expected to put a severe strain on the healthcare system. However, inadequate treatment information about achalasia among healthcare providers is likely to detain the global achalasia treatment market. Furthermore, understanding and awareness of rare disorders such as achalasia are frequently low and several patients are stressed to find adequate information about it. These factors are also anticipated to hamper the growth of the global achalasia treatment market
Achalasia Treatment market consist of various players, few key players of the market are Nestlé Skin Health (Galderma S.A.), Allergan plc, Silex Medical, LLC., Merz Pharma; Aesculap, Inc., Ipsen Biopharmaceuticals, Inc., among others.
The Achalasia Treatment market is classified into sales channel, vehicle type, medium of heat generation and region. Based on the vehicle type, the Achalasia Treatment market is bifurcated hybrid and electric vehicles. Moreover, on the basis of medium of heat generation the Achalasia Treatment market is classified into water and air heaters. On the basis of sales channel the Achalasia Treatment market is bifurcated into OEM and aftermarket.
Further, on the basis of region the market is segmented into North America, Europe, APAC, Latin America and Middle East & Africa. By region North America is expected to dominate throughout the forecast period due rising government support and initiatives.
Market segmented based on medium of end user:
• Specialty Clinics
• Research Institutes
Market segmented based on treatment:
• Non-Surgical Treatment
• Botulinum toxin type A
• Pneumatic dilation
• Surgical Treatment
• Peroral Endoscopic Myotomy (POEM)
• Heller Myotomy
Market segmented based on region:
• North America
• Rest of Europe
• Rest of Asia-Pacific
• Latin America
• Rest of Latin America
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Rest of MEA